AZ6983

AZ6983 is a novel small molecule agonist of the alpha 7 nicotinic acetylcholine receptor (α7nAChR), developed by AstraZeneca. It selectively activates α7nAChR, a ligand-gated ion channel involved in regulating inflammation. Preclinical studies in mouse models of atherosclerosis have shown that AZ6983 reduces atherosclerotic plaque development, decreases pro-inflammatory cytokines, and enhances phagocytosis by myeloid cells. Its primary mechanism of action is believed to be immunomodulation through activation of α7nAChR on immune cells. The principal indication under investigation for AZ6983 is atherosclerosis[1][2][3][5][6].